Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

Amgen logo

Amgen

Status and phase

Completed
Phase 1

Conditions

Tumors

Treatments

Drug: AMG 706
Drug: Anti-angiogenesis

Study type

Interventional

Funder types

Industry

Identifiers

NCT00093873
20030116

Details and patient eligibility

About

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

Enrollment

71 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Exclusion Criteria:

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

71 participants in 1 patient group

AMG 706
Experimental group
Description:
AMG 706 QD
Treatment:
Drug: Anti-angiogenesis
Drug: AMG 706

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems